Arca
Skip to content
Tools
Tools

Phenylketonuria

Drug research and approvals for phenylketonuria: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 31 studies of phenylketonuria are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, FDA has 4 approved and 11 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 31
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 4
  • EU medicines: 4

Recruiting now

Newest posted first, of 31 recruiting on ClinicalTrials.gov ↗

How its trials ended

165 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 39 whose ending is known, 38% met their primary endpoint, 3% missed it and 59% stopped early.

  • Completed, result not reported8149%
  • Ongoing4024%
  • Met its primary endpoint159%
  • Stopped: other or unclear106%
  • Stopped: enrollment or feasibility64%
  • Stopped: sponsor or business decision53%
  • Status unknown53%
  • Missed its primary endpoint11%
  • Stopped: lack of efficacy11%
  • Stopped: funding11%

Trials authorized in Canada

Newest first; search them all in Canada trials
Aug 27, 2026An open-label study to evaluate the long-term safety of JNT-517 in participants with phenylketonuriaRepinatrabit (JNT-517)Otsuka HoldingsPending
Sep 12, 2025A phase 3, double-blind, randomized, two-period, multicenter, placebo controlled, efficacy and safety study of JNT-517 for the treatment of participants with…Repinatrabit (JNT-517)Otsuka HoldingsOngoing
Nov 14, 2023A phase 3, randomized, crossover, open-label, active-controlled study of sepiapterin versus sapropterin in participants with phenylketonuria >2 years of ageSepiapterinPTC TherapeuticsClosed
Apr 5, 2023A phase 3, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of SYNB1934 in patients with pku (synpheny-3)SYNB1934 / Esomeprazole / Ondansetron hydrochloride dihydrateSynlogic Operating Company Inc.Ongoing
Sep 29, 2021A phase 3 study of PTC923 in subjects with phenylketonuriaPTC923PTC TherapeuticsClosed
Sep 29, 2021A phase 3 open-label study of sepiapterin (PTC923) in phenylketonuriaSepiapterin (PTC923)PTC TherapeuticsClosed

FDA orphan designations

Approved first, then open designations, newest first
Feb 27, 2026PalynziqTo reduce blood phenylalanine concentrations in adult and pediatric patients 12 years of age and older with phenylketonuria (PKU) who have…BioMarin Pharmaceutical Inc.Approved
Jul 28, 2025SephienceTreatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive…PTC Therapeutics, Inc.Approved
May 24, 2018PalynziqPalynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood…BioMarin Pharmaceutical Inc.Approved
Dec 13, 2007KuvanIndicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-)…BioMarin Pharmaceutical, Inc.Approved
Dec 13, 2025Recombinant adeno-associated virus serotype 8-based gene…Treatment of phenylketonuriaGritgen Therapeutics Co., Ltd.Designated
Oct 9, 2024An in vivo target-primed reverse transcription genome…Treatment of phenylketonuriaTessera Therapeutics, Inc.Designated
Apr 24, 2024(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)…Treatment of phenylketonuriaJnana TherapeuticsDesignated
Dec 27, 2023Small molecule chaperone to stabilize and rescue the…Treatment of PhenylketonuriaPluvia ASDesignated
Sep 8, 2023Adeno-associated virus (AAV)-based vector with an…Treatment of phenylketonuria (PKU)Sanofi US Services, Inc.Designated
May 8, 2023A phenylalanine consuming engineered bacteriaTreatment of Phenylketonuria (PKU)Synlogic Operating Company, Inc.Designated
Jan 9, 2023Recombinant adeno-associated virus serotype 8 vector…Treatment of Phenylketonuria (PKU)Nggt Inc.Designated
Mar 23, 2020L-serine, L-threonine, L-leucine, glycine, L-alanine,…Treatment of phenylketonuriaAPR Applied Pharma ResearchDesignated
Oct 21, 2019Adeno-associated virus vector encoding human phenylalanine…Treatment of phenylketonuriaBioMarin Pharmaceutical, Inc.Designated
Oct 15, 2018Recombinant lentivirus vector expressing the human…Treatment of PhenylketonuriaAmerican Gene Technologies International Inc.Designated
Oct 18, 2017A strain of modified live probiotic bacterium Escherichia…Treatment of phenylketonuria (PKU)Synlogic, Inc.Designated

Medicines authorised in the EU

Newest first
Jun 19, 2025SephienceSepiapterin · orphanPTC Therapeutics International LimitedEMA ↗
Feb 16, 2022Sapropterin DipharmaSapropterin · genericDipharma Arzneimittel GmbHEMA ↗
May 3, 2019PalynziqPegvaliase · orphanBioMarin International LimitedEMA ↗
Dec 2, 2008KuvanSapropterinBioMarin International LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.